{"groups":[{"description":"Participants received lenvatinib 14 milligrams per square meter (mg/m\\^2), capsules, orally, once daily, plus ifosfamide 3000 milligrams per square meter per day (mg/m\\^2/day), intravenously and etoposide 100 mg/m\\^2/day, intravenously. Ifosfamide and etoposide were administered on Days 1 to 3 of each 21-day cycle for up to 5 cycles. Lenvatinib was administered in continuous 21-day cycles. Treatment continued until disease progression (PD), development of unacceptable toxicity, participant choice, withdrawal of consent or discontinuation of study by the sponsor, whichever occurred first.","id":"FG000","title":"Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide"},{"description":"Participants received ifosfamide 3000 mg/m\\^2/day, intravenously and etoposide 100 mg/m\\^2/day, intravenously on Days 1 to 3 of each 21-day cycle for up to 5 cycles. Participants who had PD per response evaluation criteria in solid tumors (RECIST) version (v) 1.1 were eligible for an optional lenvatinib treatment (14 mg/m\\^2, capsules, orally, once daily in continuous 21-day cycles until next PD, development of unacceptable toxicity, participant choice, withdrawal of consent or discontinuation of study by the sponsor, whichever occurred first) plus any remaining cycles of chemotherapy if 5 cycles were not completed prior to PD.","id":"FG001","title":"Treatment Arm B: Ifosfamide + Etoposide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"10"}],"type":"Survival follow-up discontinued by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Participants transitioned to patient access program (PAP)"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Participants transitioned to managed access program (MAP)"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"25"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"41"}],"comment":"Participant Flow (including deaths in reasons of discontinuation) was based on Full Analysis Set (Full Analysis Set included all randomized participants regardless of the treatment actually received).","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"39"}],"type":"Treated (Safety Analysis Set)"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"16"}],"comment":"Participants from Treatment Arm B: Ifosfamide + Etoposide who had PD per RECIST v1.1 were eligible to receive an optional lenvatinib treatment plus any remaining cycles of chemotherapy (ifosfamide + etoposide) if 5 cycles were not completed prior to PD.","type":"Optional Lenvatinib Treatment (Arm B Only)"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"41"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 99 participants were screened, 18 failed screening. 81 participants were enrolled and randomized, out of which 78 received the study treatment.","recruitmentDetails":"Participants took part in the study at 84 investigative sites in Austria, Australia, Belgium, Hong Kong, Korea, New Zealand, Singapore, Taiwan, Czech Republic, Finland, France, Israel, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom, Canada, and the United States."}